GOG 0263 A Randomized phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/II A Cervical cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

About this Study

The purpose of this study is to find out if weekly cisplatin and concurrent radiation therapy increases the time participant's time without disease compared to radiation therapy alone.

Sponsor Protocol ID:GOG 0263
IRB Number:2010-0249
Actively Enrolling
Phase 3
July 30, 2019
Eligibility Criteria
18 years old
100 years old
Both Male and Female

Inclusion Criteria

Exclusion CriteriaPatients with tumor in the parametria, pelvic lymph nodes or any other extra uterine site or with positive surgical margins. 

Patients with septicemia or severe infection. 

Patients with intestinal obstruction or gastrointestinal bleeding. 

Patients with cervix cancer who have received any previous radiation or chemotherapy. 

Patients whose circumstances do not permit completion of the study or the required follow-up.  

Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc). 

Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.

Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute
Jackson Medical Mall - UMMC Clinics
University Hospital
Contact Information
Contact Name: Sandra Powe
Phone Number: 601-984-1965
Email: spowe@umc.edu
Principal Investigator:Wilkinson, Kelly J, M.D.
How to participate in our Clinical Trials